NRx Pharmaceuticals Inc. (NRXP) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

NRx Pharmaceuticals Inc. (NRXP)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

5.08

0.17 (3.46%)

At close: Jan 14, 2025, 3:59 PM

4.91

-3.25%

Pre-market Jan 15, 2025, 05:36 AM EST

undefined% (undefined)

Bid	4.9
Market Cap	61.38M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-2.11
PE Ratio (ttm)	-2.41
Forward PE	n/a
Analyst	Buy

Ask	5.06
Volume	1,249,687
Avg. Volume (20D)	1,006,163
Open	4.83
Previous Close	4.91
Day's Range	4.34 - 5.40
52-Week Range	1.10 - 7.33
Beta	undefined

About NRXP

NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Dec 4, 2017

Employees 2

Stock Exchange NASDAQ

Ticker Symbol NRXP

Website https://www.nrxpharma.com

Analyst Forecast

According to 4 analyst ratings, the average rating for NRXP stock is "Buy." The 12-month stock price forecast is $31, which is an increase of 510.84% from the latest price.

Buy 75.00%

Hold 0.00%

Sell 0.00%

Stock Forecasts

Why Price Moved

1 week ago · Source

+30.48%

NRX Pharmaceuticals shares are trading higher afte... Unlock content with Pro Subscription

1 week ago · Source

+35.91%

NRX Pharmaceuticals shares are trading higher after the company announced a joint-acquisition initiative with NRx Pharmaceuticals to buy the Kadima Neuropsychiatry institute.

News

1 week ago · zacks.com

Best Momentum Stocks to Buy for January 6th

NRXP, PDEX and PBYI made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 6, 2024.

1 week ago · zacks.com

New Strong Buy Stocks for January 6th

ALK, AHT, NRXP, PDEX and EGAN have been added to the Zacks Rank #1 (Strong Buy) List on January 6, 2024.

2 weeks ago · zacks.com

Best Momentum Stocks to Buy for December 30th

CCRD, TRDA and NRXP made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on December 30, 2024.

2 weeks ago · zacks.com

New Strong Buy Stocks for December 30th

CCRD, APPN, USNA, TRDA and NRXP have been added to the Zacks Rank #1 (Strong Buy) List on December 30, 2024.

2 weeks ago · zacks.com

New Strong Buy Stocks for December 26th

EGAN,ACMR, AVO, BB and NRXP have been added to the Zacks Rank #1 (Strong Buy) List on December 26, 2024.

3 weeks ago · zacks.com

New Strong Buy Stocks for December 24th

FTI, NRXP, PBYI, POWL and VMEO have been added to the Zacks Rank #1 (Strong Buy) List on December 24, 2024.

1 month ago · zacks.com

NRx Pharmaceuticals (NRXP) Upgraded to Buy: Here's Why

NRx Pharmaceuticals (NRXP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

1 month ago · seekingalpha.com

NRx Pharmaceuticals, Inc. (NRXP) Q3 2024 Earnings Call Transcript

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP ) Q3 2024 Earnings Conference Call November 18, 2024 4:30 PM ET Company Participants Matthew Duffy - Chief Business Officer Jonathan Javitt - Founder, Chairman a...

2 months ago · prismmediawire.com

NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) and HOPE Therapeutics, Inc. Announce Participation at the ThinkEquity Conference October 30, 2024

MIAMI, FL., October 23, 2024 – PRISM MediaWire – NRx Pharmaceuticals, Inc. (Nasdaq: NRXP), a clinical-stage biopharmaceutical company, (“NRx,” the “Company”) and HOPE Therapeutics, Inc.